Possibilities of applying antigestagens in therapy

Cover Page


Cite item

Full Text

Abstract

In the modern medical practice, anti-progestogen therapy is widely used where RU-486 (mifepristone) is one of its variants. However, the potential of this therapy in the treatment of various pathologies is far from exhausted. In the general medical practice, it is possible to use mifepristone (RU486 metabolite) to control hyperglycemia in patients with Cushing’s syndrome, in the treatment of endogenous hypercorticism syndrome and metastatic cancer (melanoma, breast cancer, meningioma and other localizations). In the gynecological practice, it is used for contraception and early termination of pregnancy. Of particular interest is the use of antigestagens in the therapy of uterine leiomyoma. In recent years, the conservative treatment of uterine leiomyoma, aimed at the restoration and preservation of women’s reproductive health, has become a priority task for specialists. Therapy with antigestagens, in particular mifepristone, is seen as a possible worthy alternative to invasive methods of treating uterine fibroids, in which there are still many “white spots” that need to be studied.

About the authors

Yanina A. Lebedeva

N.I. Pirogov Clinic for Advanced Medical Technologies affiliated with Saint Petersburg State University

Author for correspondence.
Email: doctor.lebedeva2015@yandex.ru

Department of of endocrine gynecology

Russian Federation, Saint Petersburg

Evgeniа B. Troik

Academician I.P. Pavlov First St. Petersburg State Medical University

Email: troik_e@mail.ru

MD, PhD, DSci (Medicine), Professor. The Department of Obstetrics, Gynecology, and Reproductive Sciences

Russian Federation, Saint Petersburg

Oleg L. Molchanov

Academician I.P. Pavlov First St. Petersburg State Medical University

Email: moleg700@mail.ru

MD, PhD, DSci (Medicine), Professor

Russian Federation, Saint Petersburg

Yuri N. Fedotov

N .I. Pirogov Clinic for Advanced Medical Technologies affiliated with Saint Petersburg State University

Email: fedotovura@yandex.ru

MD, PhD, DSci (Medicine), the Head of N.I. Pirogov Clinic for Advanced Medical Technologies affiliated with Saint Petersburg State University

Russian Federation, Saint Petersburg

References

  1. Kakade AS, Kulkarni YS. Mifepristone: current knowledge and emerging prospects. J Indian Med Assoc. 2014;112(1):36-40.
  2. Тихомиров А.Л. Миома. Патогенетическое обоснование органосохраняющего лечения. — М., 2013. [Tikhomirov AL. Mioma. Patogeneticheskoe obosnovanie organosokhranyayushchego lecheniya. Moscow; 2013. (In Russ.)]
  3. Heikinheimo O. Clinical pharmacokinetics of mifepristone. Clin Pharmacokinet. 1997;33(1):7-17. https://doi.org/10.2165/00003088-199733010-00002.
  4. Hashimoto T, Igarashi J, Hasan AU, et al. Mifepristone promotes adiponectin production and improves insulin sensitivity in a mouse model of diet-induced-obesity. PLoS One. 2013;8(11):e79724. https://doi.org/10.1371/journal.pone.0079724.
  5. Cadepond F, Ulmann A, Baulieu EE. RU486 (mifepristone): mechanisms of action and clinical uses. Annu Rev Med. 1997;48:129-156. https://doi.org/10.1146/annurev.med.48.1.129.
  6. Chen JZ, Wang JC, Gao Y, et al. A novel UPLC/MS/MS method for rapid determination of metapristone in rat plasma, a new cancer metastasis chemopreventive agent derived from mifepristone (RU486). J Pharm Biomed Anal. 2014;95:158-163. https://doi.org/10.1016/j.jpba.2014.02.026.
  7. Morgan FH, Laufgraben MJ. Mifepristone for management of Cushingʼs syndrome. Pharmacotherapy. 2013;33(3):319-329. https://doi.org/10.1002/phar.1202.
  8. Pal’chikova NA, Kuznetsova NV, Selyatitskaya VG, et al. Effects of intraperitoneal administration of Mifepristone on glucocorticoid status of experimental animals. Bull Exp Biol Med. 2016;161(2):257-260. https://doi.org/10.1007/s10517-016-3390-6.
  9. Yuen KC, Williams G, Kushner H, Nguyen D. Association between Mifepristone dose, efficacy, and tolerability in patients with Сushing syndrome. Endocr Pract. 2015;21(10):1087-1092. https://doi.org/10.4158/EP15760.OR.
  10. Wang J, Chen J, Zhu Y, et al. In vitro and in vivo efficacy and safety evaluation of metapristone and mifepristone as cancer metastatic chemopreventive agents. Biomed Pharmacother. 2016;78:291-300. https://doi.org/10.1016/j.biopha.2016.01.017.
  11. Li HW, Liao SB, Yeung WS, et al. Ulipristal acetate resembles mifepristone in modulating human fallopian tube function. Hum Reprod. 2014;29(10):2156-2162. https://doi.org/10.1093/humrep/deu210.
  12. Федеральный закон № 323-ФЗ от 21 ноября 2011 г. «Об основах охраны здоровья граждан в Российской Федерации». [Federal Law of Russian Federation No. 323-FZ of 21 Nov 2011. “Ob osnovakh okhrany zdorov’ya grazhdan v Rossiyskoy Federatsiiˮ. (In Russ.)]
  13. Mifeprex RSG, Raymond EG, Blanchard K, et al. Sixteen years of overregulation: time to unburden Mifeprex. N Engl J Med. 2017;376(8):790-794. https://doi.org/10.1056/NEJMsb1612526.
  14. Дикке Г.Б., Яроцкая В.А., Ерофеева А.В. Стратегическая оценка политики, программ и услуг в сфере непланируемой беременности, абортов и контрацепции в Российской Федерации. Совместное исследование МЗ и СР РФ и ВОЗ // Проблемы репродукции. — 2010. — Т. 16. — № 3. — С. 92–107. [Dikke GB, Yarotskaya VA, Erofeeva AV. Strategy, programs and services in the field of unplanned pregnancy, abortions and contraception in Russian Federation. Investigation of Ministry of Health and Social Development of RF and IHF. Modern reproductive technologies. 2010;16(3):92-107. (In Russ.)]
  15. Всемирная организация здравоохранения. Безопасный аборт: рекомендации для систем здравоохранения по вопросам политики и практики. — М.: ВОЗ, 2004. — 138 с. [Vsemirnaya organizatsiya zdravookhraneniya. Bezopasnyy abort: rekomendatsii dlya sistem zdravookhraneniya po voprosam politiki i praktiki. Moscow: VOZ; 2004. 138 p. (In Russ.)]
  16. Li CL, Chen DJ, Song LP, et al. Effectiveness and safety of lower doses of Mifepristone combined with Misoprostol for the termination of ultra-early pregnancy: a dose-ranging randomized controlled trial. Reprod Sci. 2015;22(6):706-711. https://doi.org/10.1177/1933719114557897.
  17. Dabash R, Chelli H, Hajri S, et al. A double-blind randomized controlled trial of mifepristone or placebo before buccal misoprostol for abortion at 14-21 weeks of pregnancy. Int J Gynaecol Obstet. 2015;130(1):40-44. https://doi.org/10.1016/j.ijgo.2015.02.023.
  18. Grossman D, White K, Harris L, et al. Continuing pregnancy after mifepristone and “reversalˮ of first-trimester medical abortion: a systematic review. Contraception. 2015;92(3):206-211. https://doi.org/10.1016/j.contraception.2015.06.001.
  19. Юлдашева О.С., Негматшаева Х.Н., Тураева Г.Ю., и др. Состояние репродуктивной функции у женщин с миомой матки // Молодой ученый. — 2016. — № 4. — С. 312–315. [Yuldasheva OS, Negmatshaeva KhN, Turaeva GY, et al. Sostoyanie reproduktivnoy funktsii u zhenshchin s miomoy matki. Molodoy uchenyy. 2016;(4):312-315. (In Russ.)]
  20. Zheng X, Sun Y, Zhang H, et al. Prospective study evaluating the effect of mifepristone on E-cadherin expression in villi in early pregnancy. Eur J Obstet Gynecol Reprod Biol. 2015;194:115-118. https://doi.org/10.1016/j.ejogrb.2015.08.004.
  21. Szamatowicz M, Kotarski J. Selective progesterone receptor modulator (ulipristal acetate — a new option in the pharmacological treatment of uterine fibroids in women. Ginekol Pol. 2013;84(3):219-222. https://doi.org/10.17772/gp/1567.
  22. Беженарь В.Ф., Комличенко Э.В., Ярмолинская М.И., и др. Инновационные подходы к восстановлению репродуктивной функции у больных миомой матки // Акушерство и гинекология. — 2016. — № 1. — С. 80–87. [Bezhenar’ VF, Komlichenko EV, Yarmolinskaya MI, et al. Innovatsionnye podkhody k vosstanovleniyu reproduktivnoy funktsii u bol’nykh miomoy matki. Akush Ginekol (Mosk). 2016;(1):80-87. (In Russ.)]. https://doi.org/10.18565/aig.2016.1.80-87.
  23. Brazert M, Korman MP, Pawelczyk LA. Applicability of selective progesterone receptor modulators in the treatment of uterine leiomyomata and their future role in the field of gynecology. Ginekol Pol. 2013;84(9):794-800. https://doi.org/10.17772/gp/1642.
  24. Engman M, Granberg S, Williams AR, et al. Mifepristone for treatment of uterine leiomyoma. A prospective randomized placebo controlled trial. Hum Reprod. 2009;24(8):1870-1879. https://doi.org/10.1093/humrep/dep100.
  25. Lu ZZ, Yan L, Zhang H, et al. Mifepristone inhibites the migration of endometrial cancer cells through regulating H19 methylation. Zhonghua Zhong Liu Za Zhi. 2016;38(6):411-416. https://doi.org/10.3760/cma.j.issn.0253-3766.2016.06.003.
  26. Тихомиров А.Л. Расширение возможностей органосохраняющего лечения миомы матки с использованием улипристала ацетата // Гинекология. — 2016. — № 1. — С. 56–60. [Tikhomirov AL. Empowering organ-preserving treatment of uterine fibroids using ulipristal acetate. Ginekologiya. 2016;(1):56-60. (In Russ.)]
  27. Зайдиева Я.З., Глазкова А.В. Лечение больных с миомой матки: факты и нерешенные вопросы // Росcийский вестник акушера-гинеколога. — 2016. — Т. 16. — № 2. — С. 37–41. [Zaydieva YZ, Glazkova AV. Treatment in patients with uterine myoma: Facts and unsolved problems. Rossiiskii vestnik akushera-ginekologa. 216;16(2):37-41. (In Russ.)]
  28. Тотчиев Г.Ф., Девятова Е.А. Миома матки: современные методы лечения // Акушерство и гинекология: новости, мнения, обучение. — 2016. — № 1. — С. 47–58. [Totchiev GF, Devyatova EA. Uterine fibroids: modern treatment methods. Akusherstvo i ginekologiya: novosti, mneniya, obuchenie. 2016;(1):47-58. (In Russ.)]
  29. Кажина М.В., Ганчар Е.П., Главацкая Е.Н., и др. Клиническая эффективность антигестагенов в терапии лейомиомы матки // Medicus. — 2016. — № 5. — С. 23–27. [Kazhina MV, Ganchar EP, Glavatskaya EN, et al. Clinical efficacy of antiprogestines in treatment of uterine leiomyoma. Medicus. 2016;(5):23-27. (In Russ.)]
  30. Engman M, Varghese S, Lagerstedt RK, et al. GSTM1 gene expression correlates to leiomyoma volume regression in response to mifepristone treatment. PLoS One. 2013;8(12):e80114. https://doi.org/10.1371/journal.pone.0080114.
  31. SantʼAnna GDS, Brum IS, Branchini G, et al. Ovarian steroid hormones modulate the expression of progesterone receptors and histone acetylation patterns in uterine leiomyoma cells. Gynecol Endocrinol. 2017;33(8):629-633. https://doi.org/10.1080/09513590.2017.1301924.
  32. Kulshrestha V, Kriplani A, Agarwal N, et al. Low dose mifepristone in medical management of uterine leiomyoma — an experience from a tertiary care hospital from north India. Indian J Med Res. 2013;137(6):1154-1162.
  33. Kapur A, Angomchanu R, Dey M. Efficacy of use of long-term, low-dose Mifepristone for the treatment of fibroids. J Obstet Gynaecol India. 2016;66(Suppl 1):494-498. https://doi.org/10.1007/s13224-016-0861-7.
  34. Yerushalmi GM, Gilboa Y, Jakobson-Setton A, et al. Vaginal mifepristone for the treatment of symptomatic uterine leiomyomata: an open-label study. Fertil Steril. 2014;101(2):496-500. https://doi.org/10.1016/j.fertnstert.2013.10.015.
  35. Esteve JL, Acosta R, Perez Y, et al. Mifepristone versus placebo to treat uterine myoma: a double-blind, randomized clinical trial. Int J Womens Health. 2013;5:361-369. https://doi.org/10.2147/IJWH.S42770.
  36. Carbonell JL, Acosta R, Perez Y, et al. Safety and effectiveness of different dosage of mifepristone for the treatment of uterine fibroids: a double-blind randomized clinical trial. Int J Womens Health. 2013;5:115-124. https://doi.org/10.2147/IJWH.S33125.
  37. Carbonell JL, Acosta R, Perez Y, et al. Treatment of uterine myoma with 2.5 or 5 mg Mifepristone daily during 3 months with 9 months posttreatment followup: randomized clinical trial. ISRN Obstet Gynecol. 2013;2013:649030. https://doi.org/10.1155/2013/649030.
  38. Леваков С.А., Шешукова Н.А. Влияние медикаментозной терапии мифепристоном на качество жизни пациенток с миомой матки // Медицинский совет. — 2017. — № 2. — С. 136–141. [Levakov SA, Sheshukova NA. The effect of treatment with mifepristone on the quality of life of patients with uterine myoma. Meditsinskiy sovet. 2017;(2):136-41. (In Russ.)]. https://doi.org/10.21518/2079-701X-2017-2-136-141.
  39. Grunberg SM, Weiss MH, Spitz IM, et al. Treatment of unresectable meningiomas with the antiprogesterone agent mifepristone. J Neurosurg. 1991;74(6):861-866. https://doi.org/10.3171/jns.1991.74.6.0861.
  40. Martineau PA, Levental M. Large endometrial polyp in a patient on long-term mifepristone therapy. J Ultrasound Med. 2000;19(7):487-489. https://doi.org/10.7863/jum.2000.19.7.487.
  41. Newfield RS, Spitz IM, Isacson C, New MI. Long-term mifepristone (RU486) therapy resulting in massive benign endometrial hyperplasia. Clin Endocrinol (Oxf). 2001;54(3):399-404. https://doi.org/10.1046/j.1365-2265.2001.01026.x.
  42. Eisinger SH, Meldrum S, Fiscella K, et al. Low-dose mifepristone for uterine leiomyomata. Obstet Gynecol. 2003;101(2):243-250. https://doi.org/10.1097/00006250-200302000-00009.
  43. Steinauer J, Pritts EA, Jackson R, Jacoby AF. Systematic review of mifepristone for the treatment of uterine leiomyomata. Obstet Gynecol. 2004;103(6):1331-1336. https://doi.org/10.1097/01.AOG.0000127622.63269.8b.
  44. Доброхотова Ю.Э., Ильина И.Ю., Гончаров И.Ю. Миома матки. Безоперационное лечение // РМЖ. — 2018. — Т. 26. — № 2-1. — С. 3–6. [Dobrokhotova YE, Il’ina IY, Goncharov IY. Mioma matki. Bezoperatsionnoe lechenie. RMZh. 2018;26(2-1):3-6. (In Russ.)]

Supplementary files

Supplementary Files
Action
1. JATS XML
Download

Copyright (c) 2019 Lebedeva Y.A., Troik E.B., Molchanov O.L., Fedotov Y.N.

Creative Commons License
This work is licensed under a Creative Commons Attribution 4.0 International License.

This website uses cookies

You consent to our cookies if you continue to use our website.

About Cookies